Tranexamic Acid for Arterial Bleeding: Indications, Dosing, and Contraindications

1. Indications in Trauma and Surgical Hemorrhage

• Early administration (within 90 minutes of injury) of 1 g IV bolus over 10 min followed by 1 g infused over 8 h reduces 28‑day mortality (adjusted risk ratio ≈ 0.64) in patients with arterial trauma or surgical bleeding. – Critical Care (Grade 1 recommendation) 1
• Giving TXA up to 3 hours after injury still confers a mortality benefit (relative risk ≈ 0.85 for bleeding‑related death). – Critical Care 1 & Anaesthesia (moderate‑quality evidence) 2
• Administering TXA later than 3 hours is linked to increased hemorrhage‑related death (relative risk ≈ 1.44) and should be avoided. – Critical Care (strong recommendation) 1 & Anaesthesia 2
• The CRASH‑2 trial (20,211 patients) demonstrated a consistent mortality reduction across all injury types, independent of the vascular source of bleeding. – Critical Care (high‑quality evidence) 1 & Anaesthesia 2
• TXA’s antifibrinolytic mechanism operates regardless of whether the bleed originates from arterial, venous, or capillary vessels. – Anaesthesia (mechanistic evidence) 3

2. Contraindications and Harm in Gastrointestinal Arterial Bleeding

• The HALT‑IT trial (12,009 patients) found no mortality benefit of TXA in acute GI hemorrhage (relative risk ≈ 0.99). – Praxis Medical Insights (Level A evidence) 4
• TXA nearly doubles the risk of venous thromboembolism in patients with GI bleeding. – Praxis Medical Insights (moderate‑quality evidence) 4
• Acidic gastric conditions degrade TXA, making it pharmacologically ineffective for upper GI arterial bleeding. – Praxis Medical Insights (mechanistic rationale) 4
• The European Association for the Study of the Liver (2022) issues a strong recommendation against TXA in variceal bleeding. – European Association for the Study of the Liver (strong recommendation) 4
• The British Society of Gastroenterology (2019) limits TXA use in lower GI bleeding to controlled clinical trials only. – British Society of Gastroenterology (conditional recommendation) 4

3. Use in Patients on Anticoagulants with Arterial Bleeding

• TXA should be employed using the same indications and dosing as in non‑anticoagulated patients (Grade 1+ recommendation). – Anaesthesia (high‑quality evidence) 3
• For traumatic arterial bleeding in anticoagulated patients, standard trauma dosing (1 g IV bolus + 1 g over 8 h) is recommended. – Anaesthesia & Critical Care (consistent evidence) [3][1]
• In gastrointestinal arterial bleeding on anticoagulants, TXA must not be given; instead, reverse the anticoagulant with agent‑specific therapies (e.g., idarucizumab for dabigatran, PCCs for warfarin, andexanet alfa for factor Xa inhibitors). – Anaesthesia & Praxis Medical Insights (strong recommendation) [3][4]
• TXA and anticoagulants act on distinct molecular targets, and no pharmacologic interaction alters TXA efficacy. – Anaesthesia (pharmacologic evidence) 3

4. Specific Clinical Contexts

4.1 Epistaxis (Nasal Arterial Bleeding)

• IV TXA reduces the 10‑day recurrence of epistaxis, irrespective of the patient’s anticoagulation status. – Anaesthesia (moderate‑quality evidence) 3
• Topical TXA (mouthwash or compress‑soaked) is effective for oral and gingival arterial bleeding. – Anaesthesia (mechanistic/clinical evidence) 3

4.2 Pelvic Fracture with Suspected Arterial Bleeding

• Immediate TXA administration is advised for suspected pelvic arterial hemorrhage. – Critical Care (strong recommendation) [1][5]
• Combine TXA with a mechanical pelvic binder and proceed to angiographic embolization if bleeding persists. – Critical Care (clinical pathway) 5

5. Safety Profile

• In trauma patients, TXA does not increase the incidence of arterial or venous thrombosis. – Critical Care & Anaesthesia (robust safety data) [1][2]
• Conversely, in patients with gastrointestinal bleeding, TXA is associated with a higher risk of venous thromboembolism. – Praxis Medical Insights (moderate‑quality evidence) 4

6. Dosing Algorithm for Arterial Bleeding

7. Implementation Pitfalls

• Every 15‑minute delay in TXA delivery reduces its efficacy; pre‑hospital administration is recommended. – Critical Care & Critical Care (2023) (implementation guidance) [1][5]
• Using TXA for gastrointestinal bleeding is contraindicated and raises thrombotic risk. – Praxis Medical Insights (strong warning) 4
• Late administration (> 3 h) in trauma increases hemorrhage‑related mortality and should be avoided. – Critical Care & Anaesthesia (strong recommendation) [1][2]

Tranexamic Acid Is Contraindicated in Gastrointestinal Bleeding and Enteric Fever

Guideline Recommendations

• The British Society of Gastroenterology (2019) restricts the use of tranexamic acid in lower gastrointestinal bleeding to clinical‑trial settings only, reflecting a lack of demonstrated benefit and safety concerns. 6
• The British Society of Gastroenterology (2019) advises that anticoagulant reversal in GI bleeding should be performed with prothrombin complex concentrate and vitamin K for warfarin, idarucizumab for dabigatran, and andexanet alfa or PCC for rivaroxaban/apixaban; tranexamic acid must not be used for this purpose. 6

Evidence Against TXA in GI Bleeding

• A meta‑analysis published in Gut (2002) found that tranexamic acid may reduce the need for surgical intervention in ulcer bleeding, but the evidence was insufficient to support routine use; further studies were recommended. 7
• The Gut (2002) guideline recommends resuscitation with crystalloids and packed red blood cells to maintain a hemoglobin >7 g/dL in stable patients with GI bleeding. 7
• The Gut (2002) guideline advises urgent upper endoscopy for patients with ongoing hemodynamic instability or fresh hematemesis to identify and treat the bleeding source. 7
• The Gut (2002) guideline suggests monitoring pulse, blood pressure, urine output, and hemoglobin every 4–6 hours to detect ongoing or recurrent bleeding. 7
• The Gut (2002) guideline recommends high‑dose intravenous proton‑pump inhibitor therapy (omeprazole 80 mg bolus followed by 8 mg/h infusion for 72 h) when peptic ulcer disease is confirmed endoscopically. 7

Risks Specific to Enteric Fever

• Enteric fever causes gastrointestinal bleeding in 10–15 % of patients via intestinal ulceration, typically after the first week of illness. 8
• Enteric fever is associated with a hypercoagulable state and thrombotic complications; adding an antifibrinolytic such as tranexamic acid would exacerbate this risk. 8
• Ceftriaxone 2 g IV daily for 14 days is recommended as first‑line therapy for suspected fluoroquinolone‑resistant enteric fever in Asia (where resistance exceeds 70 %). 8
• Blood cultures should be obtained immediately (highest yield within the first week), with stool and urine cultures obtained after the first week. 8
• Surgical consultation is advised if bleeding cannot be controlled endoscopically or if intestinal perforation is suspected, a complication occurring in 10–15 % of enteric fever cases. 8

Supportive Care and Transfusion Guidance

• The Anaesthesia (2016) guideline states that platelet transfusion should be given only when the platelet count is <50 × 10⁹/L with active bleeding; routine prophylactic platelet transfusion is not indicated. 9

Trauma Literature Not Applicable

• Analysis of the CRASH‑2 trial (Critical Care, 2013) shows that tranexamic acid reduces mortality in trauma hemorrhage when administered within 90 minutes of injury (adjusted RR 0.64, 95 % CI 0.50–0.82). 10
• The same analysis indicates that administering tranexamic acid beyond 3 hours after trauma increases hemorrhage‑related mortality (RR 1.44). 10